Heartflow (NASDAQ:HTFL) CFO Sells 5,876 Shares of Stock

by · The Markets Daily

Heartflow, Inc. (NASDAQ:HTFL – Get Free Report) CFO Vikram Verghese sold 5,876 shares of Heartflow stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $50.60, for a total value of $297,325.60. Following the completion of the transaction, the chief financial officer directly owned 248,683 shares of the company’s stock, valued at $12,583,359.80. This represents a 2.31% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Vikram Verghese also recently made the following trade(s):

  • On Thursday, September 3rd, Vikram Verghese sold 27,540 shares of Heartflow stock. The stock was sold at an average price of $49.69, for a total transaction of $1,368,462.60.

Heartflow Stock Performance

HTFL traded down $0.80 during midday trading on Friday, hitting $48.91. The company had a trading volume of 1,406,810 shares, compared to its average volume of 1,541,654. Heartflow, Inc. has a twelve month low of $20.13 and a twelve month high of $51.78. The company has a market capitalization of $4.25 billion and a PE ratio of -26.73. The firm’s 50-day simple moving average is $33.50 and its 200-day simple moving average is $29.79.

Heartflow (NASDAQ:HTFL – Get Free Report) last announced its earnings results on Thursday, August 13th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.15. Heartflow had a negative net margin of 55.82% and a negative return on equity of 23.52%. The company had revenue of $64.08 million for the quarter. The company’s revenue for the quarter was up 47.7% compared to the same quarter last year. As a group, sell-side analysts anticipate that Heartflow, Inc. will post -0.75 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have commented on HTFL shares. Weiss Ratings upgraded Heartflow from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, August 7th. Robert W. Baird set a $45.00 price target on Heartflow in a report on Friday, August 14th. Benchmark reissued a “buy” rating on shares of Heartflow in a report on Friday, August 14th. Canaccord Genuity Group upped their target price on shares of Heartflow from $37.00 to $45.00 and gave the company a “buy” rating in a research report on Friday, August 14th. Finally, JPMorgan Chase & Co. lifted their price target on shares of Heartflow from $35.00 to $45.00 and gave the stock an “overweight” rating in a research report on Friday, August 14th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Heartflow has an average rating of “Moderate Buy” and a consensus target price of $43.43.

Check Out Our Latest Research Report on Heartflow

Hedge Funds Weigh In On Heartflow

Institutional investors have recently modified their holdings of the stock. Caitong International Asset Management Co. Ltd bought a new stake in shares of Heartflow in the 4th quarter valued at about $27,000. Russell Investments Group Ltd. bought a new position in Heartflow during the 4th quarter worth approximately $45,000. Essential Partners LLC acquired a new position in Heartflow during the first quarter valued at approximately $57,000. Legal & General Group Plc bought a new stake in Heartflow in the third quarter valued at approximately $59,000. Finally, Strs Ohio acquired a new stake in Heartflow in the fourth quarter worth $99,000.

Heartflow Company Profile

(Get Free Report)

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.

Recommended Stories